TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12760406
Drug: Tobramycin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin 2.5 mg/kg/12 hr for a mean of 8 days
Study: 12760406
Drug: Gentamicin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 2.5 mg/kg/12 hr for a mean of 8 days
Study: 28576354
Drug: In-line intravenous
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-line intravenous fluid warming
Study: 21261988
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education intervention based on WHO's IMCI, consisting of eight monthly 30-minute sessions.
Study: 19050692
Drug: Trans-rectal ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-rectal ultrasound (TRUS) for biopsy
Study: 17215658
Drug: HCTZ 50
Normalized name: HCTZ 50 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ 50 mg/d
Study: 17215658
Drug: HCTZ 25
Normalized name: HCTZ 25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ 25 mg/d
Study: 17215658
Drug: OM 40
Normalized name: Aptiom 400mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM 40 mg/d (monotherapy)
Study: 14713367
Drug: sho‐saiko‐to (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: sho‐saiko‐to (2.5 g twice daily for five days)
Study: 10084580
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human GH (rhGH) and oxandrolone (OX) in combination
Study: 7552095
Drug: Daily calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily calcitriol administration
Study: 7552095
Drug: Intermittent calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent calcitriol administration
Study: 7552095
Drug: Physiologic dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic dosing of calcitriol
Study: 7552095
Drug: Pharmacologic dosing
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic dosing of calcitriol
Study: 2048803
Drug: Smoking intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking intervention program and prescription of an inhaled bronchodilator
Study: 22345878
Drug: Acamprosate 333
Normalized name: acamprosate 333 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate 333 mg TDS
Study: 20423242
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg estradiol vaginal tablets
Study: 20423242
Drug: 25 microg
Normalized name: Digoxin 125 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 microg estradiol vaginal tablets
Study: 20423242
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 10 microg and 25 microg doses
Study: 18675392
Drug: Progressive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive and supervised 21-week concurrent strength and endurance training
Study: 12637127
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol dry powder 12 microg BID
Study: 11036957
Drug: Intraportal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraportal chemotherapy (5‐fluorouracil 500 mg/m2/day in continuous infusion for 7 days and mitomycin C 10 mg/m2 at day 7)
Study: 11036957
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (systemic chemotherapy only)
Study: 11036957
Drug: Intraportal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraportal chemotherapy
Study: 1325176
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose natural interferon alfa (nIFN‐alpha)
Study: 1325176
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy (CAP)
Study: 1325176
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no maintenance treatment)
Study: 6151145
Drug: Ceruletide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceruletide (40 micrograms, intramuscularly, twice for 2 consecutive weeks)
Study: 21786162
Drug: Hay +
Normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hay + 150 g moringa leaf (T2)
Study: 21786162
Drug: Hay +
Normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hay + 300 g moringa leaf (T3)
Study: 21786162
Drug: Hay +
Normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hay + 450 g moringa leaf (T4)
Study: 12583554
Drug: Amoxicillin‐clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin‐clavulanic acid (2.2 g) and Cefazolin (2 g)
Study: 10626237
Drug: Clofazimine 50
Normalized name: clofazimine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofazimine 50 mg daily for six months in addition to the WHO regimen
Study: 10626237
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving standard WHO regimen (six doses of once a month rifampicin with daily dapsone for six months)
Study: 3636818
Drug: Z‐track intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z‐track intramuscular injection technique
Study: 27101668
Drug: Nasal endoscope
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal endoscope negative pressure cleaning and normal saline spray washing
Study: 22043464
Drug: Short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short implants (5 to 8.5 mm)
Study: 22043464
Drug: Bone augmentation
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone augmentation with autogenous bone for longer implants (>11.5 mm)
Study: 22043464
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (short implants and augmented longer implants)
Study: 19916291
Drug: Medication with
Normalized name: EUGENOL 850 mg in 1 mL DENTAL LIQUID [Walgreens Natural Eugenol/Toothache Medication with cotton pellets and tweezers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication with Omeperazole (20 mg, qd.)
Study: 11297595
Drug: Troglitazone 300
Normalized name: troglitazone 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 300 mg/day (TGZ-300)
Study: 11297595
Drug: Troglitazone 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 600 mg/day (TGZ-600)
Study: 9508155
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with chlorthalidone (12.5-25 mg/d)
Study: 8070930
Drug: Ampicillin/sulbactam (33.3/16.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin/sulbactam (33.3/16.7 mg/kg bodyweight)
Study: 27580827
Drug: Social facilitation
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social facilitation maintenance treatment (4 months, 16 outpatient group sessions)
Study: 27580827
Drug: Social facilitation
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social facilitation maintenance treatment
Study: 21736587
Drug: Robenacoxib 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robenacoxib 5 mg/kg once daily for 28 days
Study: 21736587
Drug: Robenacoxib 10
Normalized name: robenacoxib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robenacoxib 10 mg/kg once daily for 28 days
Study: 21736587
Drug: Robenacoxib 2
Normalized name: robenacoxib 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robenacoxib 2 mg/kg twice daily for 42 days
Study: 21736587
Drug: Robenacoxib 6
Normalized name: robenacoxib 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robenacoxib 6 mg/kg twice daily for 42 days
Study: 21736587
Drug: Robenacoxib 10
Normalized name: robenacoxib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robenacoxib 10 mg/kg twice daily for 42 days
Study: 18498919
Drug: Carvedilol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (0.4 mg/kg/d in children <or=62.5 kg or 25 mg/d in children >62.5 kg)
Study: 12825804
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Dalteparin 2 x 5,000U)
Study: 12825804
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin (UFH) (5,000U bolus followed by infusion to raise APTT to 1.5 times control)
Study: 23349309
Drug: Post-remission chemotherapy
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-remission chemotherapy
Study: 21315644
Drug: Induction chemoradiation
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemoradiation (60 Gy, 2 Gy/fraction; concomitant 5‐fluoro‐uracil infusion, 300 mg/m(2) per day, days 1‐5 for 6 weeks; cisplatin, 20 mg/m(2) per day, days 1‐5 during weeks 1 and 5) followed by maintenance gemcitabine (1000 mg/m(2) weekly, 3/4 weeks)
Study: 21315644
Drug: Induction gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction gemcitabine (1000 mg/m(2) weekly for 7 weeks) followed by maintenance gemcitabine (1000 mg/m(2) weekly, 3/4 weeks)
Study: 19827653
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (Control group, n = 47)
Study: 18261273
Drug: Itraconazole oral
Normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole oral solution (20 ml once a day for 15 days)
Study: 18261273
Drug: Fluconazole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (150 mg once a day for 15 days)
Study: 15238591
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (weight-adjusted intravenous)
Study: 9674293
Drug: Enalapril up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril up to 20 mg/day
Study: 3393620
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and exposure therapy
Study: 3393620
Drug: Imipramine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine and exposure therapy
Study: 27614675
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acid-based parenteral nutrition (Omegaven, Fresenius-Kabi, Germany) for 5 days postoperatively
Study: 23168119
Drug: Per oral
Normalized name: Amino Acids/Copper Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per oral endoscopic myotomy
Study: 12161101
Drug: rhGM-CSF 5
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhGM-CSF 5 mcg/kg/d for 4 days, IV
Study: 12161101
Drug: rhG-CSF 10
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhG-CSF 10 mcg/kg/d for 4 days, IV
Study: 9527776
Drug: P‐HTIG plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: P‐HTIG plus Td vaccine
Study: 7637157
Drug: Oral triazolam
Normalized name: Triazolam
DrugBank: Triazolam (DB00897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral triazolam (0.25 mg)
Study: 7637157
Drug: Oral tizanidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tizanidine (3 mg)
Study: 27633135
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (PJ) consumption, 200 ml daily for six weeks
Study: 25875324
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment group receiving business training, $150, and supervision and advising.
Study: 19436135
Drug: Light resistance
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light resistance exercise (15 min dumbbell exercise using 300 g brown‐rice‐filled fabric dumbbells)
Study: 15187817
Drug: Hypoglycaemia (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycaemia (up to 69 mg/dl)
Study: 15187817
Drug: Euglycaemic (80-109
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycaemic (80-109 mg/dl)
Study: 15187817
Drug: Diabetic (>140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetic (>140 mg/dl)
Study: 15187817
Drug: Low normal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low normal (70-79 mg/dl)
Study: 15187817
Drug: Borderline diabetics
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Borderline diabetics (126-139 mg/dl)
Study: 15187817
Drug: Impaired fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impaired fasting glucose (110-125 mg/dl)
Study: 11209624
Drug: Elective treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective treatment cohort design with randomization
Study: 9440631
Drug: One-week course
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-week course of triple therapy with bismuth subcitrate, metronidazole, and tetracycline plus ranitidine
Study: 9440631
Drug: Six-week course
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six-week course of ranitidine 300 mg/day
Study: 8517902
Drug: Heparin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (0.25 U/ml)
Study: 3683021
Drug: Oxaprozin 600
Normalized name: oxaprozin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaprozin 600 mg
Study: 3683021
Drug: Oxaprozin 1200
Normalized name: Oxaprozin
DrugBank: Oxaprozin (DB00991)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxaprozin 1200 mg
Study: 27344212
Drug: Heparin‐coated dialyzers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin‐coated dialyzers
Study: 7572630
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin alone (Control group, n = 35)
Study: 7572630
Drug: Combined intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous nitroglycerin and heparin (n = 31)
Study: 7572630
Drug: Combined intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous isosorbide dinitrate and heparin (n = 30)
Study: 6119025
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group receiving outpatient clinic treatment for high GGT levels
Study: 31562049
Drug: Mold-fermented cheese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mold-fermented cheese (MFC) 33.4 g daily for 3 months
Study: 31562049
Drug: Non-MFC (processed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-MFC (processed cheese made from mozzarella cheese and cream cheese) 33.4 g daily for 3 months
Study: 26167086
Drug: rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin (10 mg/d) monotherapy
Study: 24506429
Drug: Protease Inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease Inhibitor (PI) or Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Study: 21980934
Drug: Ultra-rush grass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-rush grass pollen immunotherapy with sublingual drops (Staloral)®
Study: 19095776
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to treatment failure
Study: 19095776
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of trials using PFS, TTP, or time to treatment failure vs. RR
Study: 16893378
Drug: Fenofibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (200 mg d(‐1))
Study: 16893378
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg d(‐1))
Study: 10385063
Drug: Calcitriol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.5 mg twice per day)
Study: 30393209
Drug: CartiNovex plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CartiNovex plus tablet
Study: 21933229
Drug: PM103 (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM103 (0.1, 1.0, 10, 30, 100 or 300 mg)
Study: 20668354
Drug: Irbesartan plus
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan plus amiodarone (irbesartan 150 mg/d, n=43)
Study: 17111172
Drug: Flupentixol (FLX)
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupentixol (FLX) 5.7 +/- 1.4 mg/day
Study: 17111172
Drug: Haloperidol (HAL)
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol (HAL) 8.5 +/- 5.5 mg/day
Study: 17111172
Drug: Risperidone (RIS)
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone (RIS) 3.6 +/- 1.3 mg/day
Study: 23582153
Drug: Histamine H1-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine H1-receptor antagonists
Study: 23582153
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of stimulation at 90 seconds
Study: 19846743
Drug: Androgen replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen replacement therapy (ART) with 1.5 mg methyl testosterone for 1 year
Study: 17043732
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate 885 mg/day for 2 weeks (Group III)
Study: 17043732
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy (all groups)
Study: 17043732
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy (Group II)
Study: 14560493
Drug: Olanzapine (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10‐20 mg)
Study: 14560493
Drug: Perphenazine (8‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine (8‐40 mg)
Study: 11099366
Drug: 6.9% CHO‐electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.9% CHO‐electrolyte solution (CE)
Study: 29618599
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/d (ATV10)
Study: 29618599
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/d (ATV80)
Study: 17095263
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 1:100,000 epinephrine buccal infiltration during each of the 5 phases of the menstrual cycle for groups 1 and 2; randomly selected day for group 3.
Study: 15866643
Drug: Alendronate (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (70 mg/week) with vitamin D and calcium
Study: 12060505
Drug: Fluconazole, 150
Normalized name: Fluconazole, 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole, 150 mg capsules, single dose repeated weekly for 2 weeks
Study: 12060505
Drug: Ketoconazole, 200
Normalized name: Ketoconazole, 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole, 200 mg tablets, single dose repeated weekly for 2 weeks
Study: 8184812
Drug: lovastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin (40 mg/day)
Study: 8184812
Drug: pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: pravastatin (40 mg/day)
Study: 2453699
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antiarrhythmic agents (quinidine, etmozin, disopyramide, mexitil, and allapinine)
Study: 25705952
Drug: Ablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative fractional 10,600‐nm CO2 laser treatment (3 treatments at 8-week intervals)
Study: 20630042
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose (600 mg IV)
Study: 16603135
Drug: High-dose acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose acute tryptophan depletion
Study: 16603135
Drug: Low-dose acute
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acute tryptophan depletion
Study: 12595913
Drug: Moclobemide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (300 to 600 mg, divided in 2 to 3 doses)
Study: 12595913
Drug: Moclobemide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (600 to 900 mg/d)
Study: 1467155
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium supplementation (magnesium pyrrolidone carboxylic acid) at a dose of 360 mg/day
Study: 24166742
Drug: Flunarizine 10
Normalized name: flunarizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine 10 mg daily along with betahistine 16 mg and paracetamol 1 gm during episodes
Study: 24166742
Drug: Betahistine and
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine and paracetamol during episodes
Study: 19777177
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with serial [(18)F] FDG-PET
Study: 16829617
Drug: MenBvac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenBvac vaccine
Study: 14530753
Drug: Standard sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sedation regimen (intravenous propofol at 0-5 mg.kg-1.hr-1 and alfentanil 30 microg.kg-1.hr-1)
Study: 10968495
Drug: Bronchodilators without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchodilators without inhaled corticosteroids
Study: 9046643
Drug: Assertion training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertion training therapy
Study: 9046643
Drug: No assertion
Approvals — FDA: no, EMA: no, PMDA: no
Description: No assertion training therapy (control)
Study: 8325071
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (cisplatin 50 mg/m2 and vindesine 3 mg/m2 for 2 courses)